"With regards to a partnership agreement to allow
Post# of 30066
Posted On: 08/01/2014 10:56:22 AM
"With regards to a partnership agreement to allow for the CLIA launch of LymPro in 2014, we are currently working through the intricacies of what such an agreement would entail. We have identified the laboratory that we believe has the technical know-how and marketing capabilities required for the launch of the LymPro Test both within the clinical trials setting to support pharmaceutical development, as well as a commercial launch under CLIA. We expect to be in a position to deliver definitive information to the marketplace over the summer. We believe the data to be released at AAIC and potentially the #C4CT Summit will increase the value of LymPro and give us additional leverage in negotiations.
Following the release of this data, we intend to outline a forecast for LymPro revenues and market uptake in our second quarter earnings conference call that will provide the basis for financial projections. We continue to make progress implementing our reimbursement strategy, which will give the Company additional leverage in potential partnership negotiations.
We believe LymPro could become the standard blood test for Alzheimer’s disease in the marketplace and we intend to move rapidly and diligently to unlock LymPro’s inherent value."
Following the release of this data, we intend to outline a forecast for LymPro revenues and market uptake in our second quarter earnings conference call that will provide the basis for financial projections. We continue to make progress implementing our reimbursement strategy, which will give the Company additional leverage in potential partnership negotiations.
We believe LymPro could become the standard blood test for Alzheimer’s disease in the marketplace and we intend to move rapidly and diligently to unlock LymPro’s inherent value."
(0)
(0)